Jeffrey Ritter, MD
Rheumatology · Miami, FLNPI 1891761508
Payments from drug & device makers
Across 770 payments — averaging $73.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$19K
- Mallinckrodt Hospital Products Inc.$14K
- AbbVie$9K
- Mallinckrodt Enterprises LLC$6K
- Amgen$2K
- Novartis$1K
- plus $6K from 32 others
What the payments were for
- Consulting fees$1,7004%
- Speaking & faculty fees$21,05055%
- Grants$2401%
- Travel & lodging$2,0015%
- Food & beverage$13,51435%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 20 | $18,716 |
| Mallinckrodt Hospital Products Inc. | 80 | $14,180 |
| AbbVie | 122 | $8,983 |
| Mallinckrodt Enterprises LLC | 13 | $5,751 |
| Amgen(2 entities) | 165 | $2,356 |
| Novartis | 66 | $1,315 |
| Johnson & Johnson(2 entities) | 91 | $1,125 |
| UCB, Inc. | 37 | $638 |
| ANI Pharmaceuticals, Inc. | 23 | $628 |
| Lilly USA, LLC | 26 | $482 |
| Aurinia Pharma U.S., Inc. | 19 | $473 |
| Radius Health, Inc. | 14 | $303 |
| GSK | 15 | $275 |
| AstraZeneca(2 entities) | 12 | $214 |
| Fresenius Kabi USA, LLC | 6 | $179 |
| Sanofi | 7 | $159 |
| Kiniksa Pharmaceuticals International, PLC | 6 | $136 |
| Alvogen Inc | 7 | $126 |
| Janssen Scientific Affairs, LLC | 1 | $102 |
| Organon | 7 | $99 |
| E.r. Squibb & Sons, L.L.C. | 5 | $96 |
| Boehringer Ingelheim | 3 | $82 |
| Biotronik NRO, Inc. | 2 | $80 |
| Bioventus LLC | 3 | $59 |
| Pacira Pharmaceuticals Incorporated | 3 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Tersera Therapeutics LLC | 2 | $49 |
| Bristol Myers Squibb | 2 | $47 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Ascend Therapeutics US, LLC | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Tonix Medicines, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $19 |
| Fidia Pharma USA Inc. | 1 | $17 |
| Saluda Medical Americas, Inc. | 1 | $15 |
| Sandoz | 1 | $14 |
| Medexus Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$56,943 in reported general payments places this provider in the 70th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 32 | $285,071 |
| ForteoTeriparatide | 25 | $108,562 |
| ProliaDenosumab | 60 | $92,665 |
| Cimzia (2 Pack)Certolizumab Pegol | 15 | $79,602 |
| TymlosAbaloparatide | 23 | $77,457 |
| ActemraTocilizumab | 15 | $69,077 |
| Colchicine | 50 | $6,974 |
| Hydroxychloroquine Sulfate | 247 | $6,577 |
| MethotrexateMethotrexate Sodium | 270 | $5,670 |
| Mycophenolate Mofetil | 46 | $4,826 |
| Ibandronate Sodium | 141 | $4,479 |
| Zoledronic AcidZoledronic Acid/Mannitol-Water | 13 | $3,756 |
| Gabapentin | 134 | $2,059 |
| Sulfasalazine | 73 | $1,870 |
| Tramadol Hcl | 107 | $1,860 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo | $482 | $108,56225 claims |
| AmgenProlia | $2,356 | $92,66560 claims |
| UCB, Inc.Cimzia (2 Pack) | $638 | $79,60215 claims |
| Radius Health, Inc.Tymlos | $303 | $77,45723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 453 rheumatology providers in Florida.
Other rheumatology in Miami
- Marimer Rensoli VelazquezMiami$12.2M
- Rawan JumeanMiami$1.6M
- Elana ObersteinMiami$1M
- Gary SterbaMiami$883K
- Azarel AbinaderMiami$689K
- Michael WeitzMiami$673K
- Joseph la ContiMiami$661K
- Dana AschermanMiami$491K
- Martha Hernandez IllasFort Lauderdale$25M
- Carlos SesinMiami Beach$19M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.